Literature DB >> 29788442

Response to the comment on "Trivalent CAR T cells overcome interpatient antigenic variability in glioblastoma" by Bielamowicz et al.

Sujith K Joseph1,2,3, Hebatalla Samaha1,2,3,4, Kevin Bielamowicz1,2,3,5, Nabil Ahmed1,2,3,4,5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29788442      PMCID： PMC6280136          DOI： 10.1093/neuonc/noy079

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN： 1522-8517            Impact factor:   12.300


× No keyword cloud information.
  12 in total

1.  The somatic genomic landscape of glioblastoma.

Authors:  Cameron W Brennan; Roel G W Verhaak; Aaron McKenna; Benito Campos; Houtan Noushmehr; Sofie R Salama; Siyuan Zheng; Debyani Chakravarty; J Zachary Sanborn; Samuel H Berman; Rameen Beroukhim; Brady Bernard; Chang-Jiun Wu; Giannicola Genovese; Ilya Shmulevich; Jill Barnholtz-Sloan; Lihua Zou; Rahulsimham Vegesna; Sachet A Shukla; Giovanni Ciriello; W K Yung; Wei Zhang; Carrie Sougnez; Tom Mikkelsen; Kenneth Aldape; Darell D Bigner; Erwin G Van Meir; Michael Prados; Andrew Sloan; Keith L Black; Jennifer Eschbacher; Gaetano Finocchiaro; William Friedman; David W Andrews; Abhijit Guha; Mary Iacocca; Brian P O'Neill; Greg Foltz; Jerome Myers; Daniel J Weisenberger; Robert Penny; Raju Kucherlapati; Charles M Perou; D Neil Hayes; Richard Gibbs; Marco Marra; Gordon B Mills; Eric Lander; Paul Spellman; Richard Wilson; Chris Sander; John Weinstein; Matthew Meyerson; Stacey Gabriel; Peter W Laird; David Haussler; Gad Getz; Lynda Chin
Journal:  Cell       Date:  2013-10-10       Impact factor: 41.582

2.  EphA2 as a novel molecular marker and target in glioblastoma multiforme.

Authors:  Jill Wykosky; Denise M Gibo; Constance Stanton; Waldemar Debinski
Journal:  Mol Cancer Res       Date:  2005-10       Impact factor: 5.852

3.  The human protein atlas: A spatial map of the human proteome.

Authors:  Peter J Thul; Cecilia Lindskog
Journal:  Protein Sci       Date:  2017-10-10       Impact factor: 6.725

4.  The Human Protein Atlas--a tool for pathology.

Authors:  F Pontén; K Jirström; M Uhlen
Journal:  J Pathol       Date:  2008-12       Impact factor: 7.996

5.  T cells redirected to EphA2 for the immunotherapy of glioblastoma.

Authors:  Kevin K H Chow; Swati Naik; Sunitha Kakarla; Vita S Brawley; Donald R Shaffer; Zhongzhen Yi; Nino Rainusso; Meng-Fen Wu; Hao Liu; Yvonne Kew; Robert G Grossman; Suzanne Powell; Dean Lee; Nabil Ahmed; Stephen Gottschalk
Journal:  Mol Ther       Date:  2012-10-16       Impact factor: 11.454

6.  Immunotherapy for osteosarcoma: genetic modification of T cells overcomes low levels of tumor antigen expression.

Authors:  Nabil Ahmed; Vita S Salsman; Eric Yvon; Chrystal U Louis; Laszlo Perlaky; Winfried S Wels; Meghan K Dishop; Eugenie E Kleinerman; Martin Pule; Cliona M Rooney; Helen E Heslop; Stephen Gottschalk
Journal:  Mol Ther       Date:  2009-06-16       Impact factor: 11.454

7.  HER2-specific T cells target primary glioblastoma stem cells and induce regression of autologous experimental tumors.

Authors:  Nabil Ahmed; Vita S Salsman; Yvonne Kew; Donald Shaffer; Suzanne Powell; Yi J Zhang; Robert G Grossman; Helen E Heslop; Stephen Gottschalk
Journal:  Clin Cancer Res       Date:  2010-01-12       Impact factor: 12.531

8.  Tandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen escape.

Authors:  Meenakshi Hegde; Malini Mukherjee; Zakaria Grada; Antonella Pignata; Daniel Landi; Shoba A Navai; Amanda Wakefield; Kristen Fousek; Kevin Bielamowicz; Kevin K H Chow; Vita S Brawley; Tiara T Byrd; Simone Krebs; Stephen Gottschalk; Winfried S Wels; Matthew L Baker; Gianpietro Dotti; Maksim Mamonkin; Malcolm K Brenner; Jordan S Orange; Nabil Ahmed
Journal:  J Clin Invest       Date:  2016-07-18       Impact factor: 14.808

9.  Comprehensive genomic characterization defines human glioblastoma genes and core pathways.

Authors: 
Journal:  Nature       Date:  2008-09-04       Impact factor: 49.962

10.  Intratumoral heterogeneity identified at the epigenetic, genetic and transcriptional level in glioblastoma.

Authors:  Nicole R Parker; Amanda L Hudson; Peter Khong; Jonathon F Parkinson; Trisha Dwight; Rowan J Ikin; Ying Zhu; Zhangkai Jason Cheng; Fatemeh Vafaee; Jason Chen; Helen R Wheeler; Viive M Howell
Journal:  Sci Rep       Date:  2016-03-04       Impact factor: 4.379
View more
  3 in total

Review 1.  Immunotherapy Against Gliomas: is the Breakthrough Near?

Authors:  Rimas V Lukas; Derek A Wainwright; Craig M Horbinski; Fabio M Iwamoto; Adam M Sonabend
Journal:  Drugs       Date:  2019-11       Impact factor: 9.546

Review 2.  Strategies to Enhance the Efficacy of T-Cell Therapy for Central Nervous System Tumors.

Authors:  Deepak Upreti; David Bakhshinyan; Darin Bloemberg; Parvez Vora; Chitra Venugopal; Sheila K Singh
Journal:  Front Immunol       Date:  2020-11-12       Impact factor: 7.561

Review 3.  The Great War of Today: Modifications of CAR-T Cells to Effectively Combat Malignancies.

Authors:  Andriy Zhylko; Magdalena Winiarska; Agnieszka Graczyk-Jarzynka
Journal:  Cancers (Basel)       Date:  2020-07-24       Impact factor: 6.639
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.